Journal
NEUROPHARMACOLOGY
Volume 61, Issue 3, Pages 408-413Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.neuropharm.2011.02.017
Keywords
Serotonin; htr1a; Depression; Treatment-resistant; SSRI; Chronic stress; Animal models
Categories
Funding
- NIMH NIH HHS [R37 MH068542, T32 MH015174-35, R01 MH091427, T32 MH015174, K08 MH076083] Funding Source: Medline
Ask authors/readers for more resources
Depression is a polygenic and highly complex psychiatric disorder that is currently a major burden on society. Depression is highly heterogeneous in presentation and frequently exhibits high comorbidity with other psychiatric and somatic disorders. Commonly used treatments, such as selective serotonin reuptake inhibitors (SSRIs), are not ideal since only a subset of patients achieve remission. In addition, the reason why some individuals respond to SSRIs while others don't are unknown. Here we begin to ask what the basis of treatment resistance is, and propose new strategies to model this phenomenon in animals. We focus specifically on animal models that offer the appropriate framework to study treatment resistance with face, construct and predictive validity. This article is part of a Special Issue entitled 'Serotonin: The New Wave'. Published by Elsevier Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available